Competitor Analysis: Insulin
Product description
The Competitive Intelligence Report Insulin as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant insulin and insulin analogs for the treatment of type 1 and type 2 diabetes mellitus. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Total sales of branded recombinant human insulin and insulin analog products in regulated markets were US$ 18.8 bln. This huge market potential has to be defended by the major players and attracts interest from newcomers, technology developers and biosimilar companies. New developments are focused on ultra-fast and ultra-long acting insulins and convenient combinations. A strongly emerging class are oral presentation forms of insulin in clinical development.
The report provides information on the marketed insulin preparations and includes a compilation of current active projects in research and development of novel insulin products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of insulin products and projects. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Insulin as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant insulin and insulin analogs for the treatment of type 1 and type 2 diabetes mellitus. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Total sales of branded recombinant human insulin and insulin analog products in regulated markets were US$ 18.8 bln. This huge market potential has to be defended by the major players and attracts interest from newcomers, technology developers and biosimilar companies. New developments are focused on ultra-fast and ultra-long acting insulins and convenient combinations. A strongly emerging class are oral presentation forms of insulin in clinical development.
The report provides information on the marketed insulin preparations and includes a compilation of current active projects in research and development of novel insulin products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of insulin products and projects. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
- 2012 Sales of branded recombinant human insulins in regulated markets
- 2012 Sales of branded short-acting recombinant human insulin analogs in regulated markets
- 2012 Sales of branded long-acting recombinant human insulin analogs in regulated markets
- Rhu insulin (2nd generation) in regulated markets
- Biosimilar rhu insulin (2nd generation) in regulated markets
- Rhu insulin analogs (3rd generation) in regulated markets
- Biosimilar rhu insulin analogs (3rd generation) in regulated markets
- Ultra-long acting rhu insulin formulations and insulin analogs (4th generation)
- Ultra-fast acting rhu insulin formulations and insulin analogs (4th generation)
- Combinations of modern basal and prandial insulin & analogs (4th generation)
- Combinations of insulin & GLP-1 agonist (4th generation)
- Other combinations with insulin
- Oral and Transbuccal Insulins (5th generation)
- Inhaled and transdermal insulin
- Novel approaches for insulin therapy
- Rhu insulin (2nd generation) in non-regulated markets: India
- Rhu insulin (2nd generation) in non-regulated markets: China
- Rhu insulin (2nd generation) in non-regulated markets: Other Territories
- Modern insulin analogs (3rd generation) in non-regulated markets
- Animal insulins (1st generation)
- Corporate Insulin Product Portfolios and R&D Pipelines
